The earnings call reflected a balanced view with significant growth in Manufacturer Solutions and brand partnerships, offset by declines in prescription transaction revenue due to external factors. The company is optimistic about future growth opportunities and strategic initiatives.

Company Guidance

During the GoodRx Third Quarter 2025 Earnings Call, the company provided guidance on several key metrics. Total revenue for the third quarter was reported at $196 million, marking a $1 million increase from the prior year, with a notable 54% year-over-year growth in Manufacturer Solutions revenue, reaching $43.4 million. However, prescription transaction revenue declined by 9% compared to the previous year, primarily due to the impact of Rite Aid store closures and lower transaction volume in their integrated savings program. The company maintained its full-year revenue guidance, anticipating at least $792 million, while adjusted EBITDA for the quarter stood at $66.3 million, reflecting a 2% increase with a margin of 33.8%. GoodRx highlighted its strategic efforts to expand partnerships, enhance brand awareness, and engage in policy discussions to leverage market shifts toward greater price transparency and direct-to-consumer access, which are expected to be advantageous for the company's growth in 2026.

Manufacturer Solutions Revenue Growth

Strong results with 54% year-over-year revenue growth in Manufacturer Solutions, driven by new brand sales and expanded partnerships.

Partnership Expansions

Expanded access and affordability programs with leading pharmaceutical manufacturers like Novo Nordisk and Amgen, and strengthened retail partnerships such as the RxSmartSaver counter solution launch at Kroger.

New Campaign and Brand Awareness

Launch of the new Savings Wrangler campaign increasing unaided awareness and GoodRx search volumes.

Adjusted EBITDA Increase

Adjusted EBITDA was $66.3 million, an increase of 2% year-over-year, with a margin improvement of 50 basis points.

GoodRx Holdings (GDRX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

GDRX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Feb 26, 2026	2025 (Q4)	0.09 / -	0.09	―	―	―
Nov 04, 2025	2025 (Q3)	0.09 / 0.08	0.08	0.00% (0.00)	―
Aug 06, 2025	2025 (Q2)	0.10 / 0.09	0.08	12.50% (<+0.01)	―
May 07, 2025	2025 (Q1)	0.10 / 0.09	0.08	12.50% (<+0.01)	―
Feb 27, 2025	2024 (Q4)	0.09 / 0.09	0.08	12.50% (<+0.01)
Nov 07, 2024	2024 (Q3)	0.09 / 0.08	0.06	33.33% (+0.02)	―
Aug 08, 2024	2024 (Q2)	0.09 / 0.08	0.07	14.29% (<+0.01)	―
May 09, 2024	2024 (Q1)	0.08 / 0.08	0.07	14.29% (<+0.01)	―
Feb 29, 2024	2023 (Q4)	0.07 / 0.08	0.07	14.29% (<+0.01)	―
Nov 09, 2023	2023 (Q3)	0.06 / 0.06	0.07	-14.29% (-0.01)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

GDRX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 04, 2025	$3.26	$3.33	+2.15%
Aug 06, 2025	$4.34	$3.47	-20.05%
May 07, 2025	$3.79	$4.24	+11.87%
Feb 27, 2025	$4.89	$4.98	+1.84%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does GoodRx Holdings (GDRX) report earnings?

GoodRx Holdings (GDRX) is schdueled to report earning on Feb 26, 2026, Before Open (Confirmed).

What is GoodRx Holdings (GDRX) earnings time?

GoodRx Holdings (GDRX) earnings time is at Feb 26, 2026, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is GDRX EPS forecast?

GDRX EPS forecast for the fiscal quarter 2025 (Q4) is 0.09.

GoodRx Holdings (GDRX) Earnings News

GoodRx Stock (NASDAQ:GDRX) Gained on Upbeat Q4 Preliminary Results

Premium

Market News

GoodRx Stock (NASDAQ:GDRX) Gained on Upbeat Q4 Preliminary Results

2y ago

GDRX

See More GDRX News >